SCHEMBL864043

SCHEMBL864043

Fc1ccc(-c2nnc3ccc(-c4ccc5[nH]ccc5c4)nn23)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 5/20 0.43
PDE1A P54750 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
PDE3B Q13370 1/20 0.42
PDE1C Q14123 1/20 0.42
PDE3A Q14432 1/20 0.42
PDE11A Q9HCR9 1/20 0.42
PDE10A Q9Y233 1/20 0.42
DYRK3 O43781 3/20 0.41
CCNT1 O60563 3/20 0.41
CDK9 P50750 3/20 0.41
CDK5 Q00535 3/20 0.41
DYRK1A Q13627 3/20 0.41
CDK5R1 Q15078 3/20 0.41
DYRK2 Q92630 3/20 0.41
DYRK1B Q9Y463 3/20 0.41
CCNA2 P20248 2/20 0.41
CDK2 P24941 2/20 0.41
GUSB P08236 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL863333 0.85 GUSB (0.43) METDYRK3CCNT1CDK9CDK5
SCHEMBL863630 0.84 NPC1 (0.52) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL863714 0.78 DYRK3 (0.46) METDYRK3CCNT1CDK9CDK5
SCHEMBL863591 0.73 MET (0.45) METPDE1APDE4CPDE4DPDE3B
SCHEMBL15364821 0.72 ALDH1A1 (0.50) CYP3A4BRD4
SCHEMBL16009418 0.70 DYRK3 (0.77) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL2961538 0.66 DYRK3 (0.56) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL21643998 0.65 DYRK3 (0.67) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL14077050 0.65 BRD4 (0.48) GUSBCHRNA7BRD4NPC1
SCHEMBL29740190 0.64 DYRK3 (0.45) DYRK3CCNT1CDK9CDK5DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865719-B2 Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-10-21 US disclosed
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS CHRNA7, CHRNA5, CHRNA1 MET 4368/4885PDE1A 411/4885PDE4C 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.